Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.
about
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production.RNA-Seq Analysis of Gene Expression, Viral Pathogen, and B-Cell/T-Cell Receptor Signatures in Complex Chronic Disease.New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.
P2860
Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Autoantibodies, complement and ...... personalized medicine in SLE.
@en
Autoantibodies, complement and ...... personalized medicine in SLE.
@nl
type
label
Autoantibodies, complement and ...... personalized medicine in SLE.
@en
Autoantibodies, complement and ...... personalized medicine in SLE.
@nl
prefLabel
Autoantibodies, complement and ...... personalized medicine in SLE.
@en
Autoantibodies, complement and ...... personalized medicine in SLE.
@nl
P2093
P2860
P356
P1433
P1476
Autoantibodies, complement and ...... r personalized medicine in SLE
@en
P2093
P2860
P304
P356
10.1177/0961203316640922
P50
P577
2016-07-01T00:00:00Z